Investigational new drugs to treat brain metastasis from non-small cell lung cancer.

IF 4.9 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert opinion on investigational drugs Pub Date : 2025-07-11 DOI:10.1080/13543784.2025.2532449

Pasquale Vitale, Giuseppe Lamberti, Ilaria di Giovanni, Raffaele Addeo

{"title":"Investigational new drugs to treat brain metastasis from non-small cell lung cancer.","authors":"Pasquale Vitale, Giuseppe Lamberti, Ilaria di Giovanni, Raffaele Addeo","doi":"10.1080/13543784.2025.2532449","DOIUrl":null,"url":null,"abstract":"Introduction: Lung cancer is a leading cause of cancer-related mortality. Brain metastasis (BM) has a high incidence in non-small cell lung cancer (NSCLC) and represents a devastating complication associated with poor prognosis and symptoms that significantly reduce the quality of life (QOL) in patients. Managing and controlling BM is critical for prolonging survival and improving QOL. Surgical resection, stereotactic radiosurgery, and whole-brain radiation therapy are key treatment modalities for patients with NSCLC and BM.Areas covered: Molecular targeted drugs developed against driver gene mutations and immune checkpoint inhibitors have shown efficacy against BM. This review examines newly approved therapies by conducting a literature search on these topics. Therefore, it is essential to determine the most appropriate local and systemic therapies and the optimal timing to maximize overall survival and QOL.Expert opinion: Despite the effectiveness of new drugs, a high mortality rate persists. We discuss future strategies for overcoming resistance and progression.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1-14"},"PeriodicalIF":4.9000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543784.2025.2532449","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Lung cancer is a leading cause of cancer-related mortality. Brain metastasis (BM) has a high incidence in non-small cell lung cancer (NSCLC) and represents a devastating complication associated with poor prognosis and symptoms that significantly reduce the quality of life (QOL) in patients. Managing and controlling BM is critical for prolonging survival and improving QOL. Surgical resection, stereotactic radiosurgery, and whole-brain radiation therapy are key treatment modalities for patients with NSCLC and BM.

Areas covered: Molecular targeted drugs developed against driver gene mutations and immune checkpoint inhibitors have shown efficacy against BM. This review examines newly approved therapies by conducting a literature search on these topics. Therefore, it is essential to determine the most appropriate local and systemic therapies and the optimal timing to maximize overall survival and QOL.

Expert opinion: Despite the effectiveness of new drugs, a high mortality rate persists. We discuss future strategies for overcoming resistance and progression.

查看原文本刊更多论文

治疗非小细胞肺癌脑转移的新药研究。

肺癌是癌症相关死亡的主要原因。脑转移（BM）在非小细胞肺癌（NSCLC）中发病率很高，是一种毁灭性的并发症，与预后不良和显著降低患者生活质量（QOL）的症状相关。管理和控制BM对于延长生存期和改善生活质量至关重要。手术切除、立体定向放射外科和全脑放射治疗是非小细胞肺癌和脑转移患者的主要治疗方式。涉及领域：针对驱动基因突变和免疫检查点抑制剂开发的分子靶向药物已显示出对BM的有效性。本综述通过对这些主题的文献检索来审查新批准的治疗方法。因此，确定最合适的局部和全身治疗以及最佳时机以最大限度地提高总生存率和生活质量是至关重要的。专家意见：尽管新药有效，但死亡率仍然很高。我们讨论了克服阻力和进步的未来策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.